Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1272

Shown on this page

Current sort

Live official records

Conditions: Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Interventions: DCC-2812; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri + 5 more

Conditions: Osteomyelitis Tibia, Tibial Fractures, Open Tibia Fracture
Interventions: Antibiotic coated intramedullary Nail, Standard Intramedullary Nail; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 15
States / cities: Gainesville, Florida • Temple Terrace, Florida • Macon, Georgia + 12 more

Conditions: Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Interventions: Aficamten, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 24
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Stage I Lung Cancer, Stage II Lung Cancer
Interventions: Cryosurgery, Robotic Bronchoscopy, Bronchoscopy with Biopsy, Resection, Chest Radiography, Computed Tomography, Biospecimen Collection, Electronic Health Record Review; Procedure · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Genetic Disease
Interventions: Genome Informed Risk Assessment (GIRA) report; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 3 Years to 75 Years
Enrollment: 26,877 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2030
U.S. locations: 12
States / cities: Birmingham, Alabama • Tempe, Arizona • Chicago, Illinois + 7 more

Conditions: Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Interventions: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 11
States / cities: Clovis, California • Los Angeles, California • Newport Beach, California + 6 more

Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Nemtabrutinib, Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus); Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Prostate Adenocarcinoma
Interventions: Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin; Drug · Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 567
States / cities: Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more

Conditions: Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Interventions: Not listed
Lead sponsor: American Thrombosis and Hemostasis Network; Network
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2035
U.S. locations: 76
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 60 more

Conditions: Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
Interventions: Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Imaging Agent, Neck Dissection, Planar Imaging, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography; Procedure · Other · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2036
U.S. locations: 106
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 80 more

Conditions: Heart Failure, Transplant; Failure, Heart
Interventions: Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS); Device
Lead sponsor: XVIVO Perfusion; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 20
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Acute Ischemic Stroke
Interventions: TAK-755, Placebo; Biological · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 6 more

About this Vanderbilt University Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Vanderbilt University Medical Center

Filter and sort this campus

Live official records

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial

The Electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

XVIVO Heart Perfusion System (XHPS) With Supplemented XVIVO Heart Solution (SXHS)

A Study of TAK-755 in Adults With Acute Ischemic Stroke

About this Vanderbilt University Medical Center institution page